Biologic Disease-Modifying Antirheumatic Drugs
نویسنده
چکیده
1. Distinguish between biologic DMARD use and nonbiologic DMARD use in the treatment of rheumatoid arthritis (RA). 2. Assess the differences between classes of biologic disease-modifying antirheumatic drug (DMARD) therapy. 3. Based on individual patient characteristics, construct a treatment and monitoring plan for a patient with RA and, when appropriate, include biologic DMARD therapy. 4. Justify switching agents or usingcombination therapy with nonbiologic DMARDs when treatment with DMARD monotherapy fails. 5. Evaluate the need for tuberculosis screening and vaccinations in patients either starting or currently receiving biologic DMARDs. 6. Evaluate the precautions, contraindications, and warnings involving the use of biologic DMARDs in high-risk patients. Introduction
منابع مشابه
Biologic monotherapy for the treatment of rheumatoid arthritis
Methotrexate monotherapy for rheumatoid arthritis is considered efficacious and safe, but an inadequate treatment response and intolerance are common. Patients unresponsive to methotrexate or other disease-modifying antirheumatic drugs may receive biologic disease-modifying antirheumatic drugs (bDMARDs) as monotherapy, or in combination with methotrexate. Of the 17 bDMARD monotherapy clinical t...
متن کاملPharmacologic Treatment of Arthritis in Children*
The treatment of juvenile idiopathic arthritis (JIA) is largely based on multicenter pharmaceutical studies, individual patient responses, and physician experience, although consensus guidelines are lacking for patients not responsive to conventional treatment. Pharmacologic treatment is driven by the subtype of JIA and disease severity. Nonsteroidal anti-inflammatory drugs, disease-modifying a...
متن کاملEfficacy and safety of methotrexate in combination with other non-biologic disease-modifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritis.
Methotrexate (MTX) is well-established as the "anchor drug" for patients with rheumatoid arthritis (RA), to be used early and aggressively, with higher long-term effectiveness, tolerability, and safety than any other disease-modifying antirheumatic drug (DMARD). However, about 20% to 40% of patients experience incomplete responses to MTX and require further therapy, with options including other...
متن کاملPharmacotherapy Options in Rheumatoid Arthritis
Drugs form the mainstay of therapy in rheumatoid arthritis (RA). Five main classes of drugs are currently used: analgesics, non-steroidal anti-inflammatories (NSAIDs), glucocorticoids, nonbiologic and biologic disease-modifying antirheumatic drugs. Current clinical practice guidelines recommend that clinicians start biologic agents if patients have suboptimal response or intolerant to one or tw...
متن کاملBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
Clinical evidence demonstrates coadministration of tumour necrosis factor inhibitor (TNFi) agents and methotrexate (MTX) is more efficacious than administration of TNFi agents alone in patients with rheumatoid arthritis, leading to the perception that coadministration of MTX with all biologic agents or oral disease-modifying antirheumatic drugs is necessary for maximum efficacy. Real-life regis...
متن کامل